Targeting Cancer With Tyrosine Kinase Inhibition in Frontline HCC

Key Factors for Choosing Frontline Hepatocellular Carcinoma Therapy

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed the available therapy options for a patient with advanced hepatocellular carcinoma.

Determining Need for Biopsy in Suspected Hepatocellular Carcinoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.

Physicians Discuss Their Impressions of Recent IO/TKI Trials for HCC

During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.

Significance of Lenvatinib/Pembrolizumab Vs Lenvatinib Outcomes in HCC

During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.

Discussing the LEAP-002 Trial of Lenvatinib Plus Pembrolizumab in HCC

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.

Interpreting Results From New and Previous Trials of Lenvatinib in HCC

During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.

Considering Treatment for Patients with HCC and Autoimmune Disease

During a live virtual event, Daneng Li, MD, discussed the case of a 77-year-old woman with stage IV hepatocellular cancer and a Child-Pugh score of A. This is the first of 2 articles from this event.

Part 2: Managing Frontline Lenvatinib Therapy for High-Risk HCC

Pierre Gholam, MD, discussed with participants concerning the toxicity and management of lenvatinib for hepatocellular cancer and how it compares with sorafenib.

Part 1: Selecting Systemic Therapy in HCC With Serious Comorbidities

During a live virtual event, Pierre Gholam, MD, discussed treatment options for a patient with hepatocellular carcinoma who had serious medical conditions including cirrhosis, Crohn's disease, and variceal bleeding.

Lenvatinib Shows Noninferior Survival Outcomes and Improved PFS in HCC

Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.

Part 2: Factors for Considering Transplant or Immunotherapy in HCC

During a live virtual event, Richard S. Finn, MD, discussed the process of selecting frontline treatment for hepatocellular carcinoma including liver and kidney transplants and immunotherapy agents.

Part 1: Using Scans and Biopsy to Diagnose HCC

During a live virtual event, Richard S. Finn, MD, discussed the process of diagnosing liver cancer after a CT scan detected tumors and whether a biopsy was needed.